Open AccessReview on Approved and Inprogress COVID-19 Vaccines
Author(s) -
Amir Farnudian-Habibi,
Mobina Mirjani,
Vahideh Montazer,
Shima Aliebrahimi,
Iman Katouzian,
Saeed Abdolhosseini,
Ali Rahmani,
Hossein Keyvani,
Seyed Nasser Ostad,
Mazda RadMalekshahi
Publication year - 2022
Language(s) - English
Resource type - Journals
ISSN - 1726-6882
DOI - 10.5812/ijpr.124228
Subject(s) - covid-19 , dna vaccination , virology , reverse vaccinology , outbreak , medicine , computational biology , biology , immunology , epitope , immunization , immune system , antibody , infectious disease (medical specialty) , disease , pathology
: The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.